Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00020878 · ClinicalTrials.gov registry record · Phase 2
Celecoxib in Preventing Non-Small Cell Lung Cancer in Tobacco Smokers
A Phase 2 study, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT00020878 is a Phase 2 study that has completed, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 21 participants.
The verdict
NCT00020878, a Phase 2 study, has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. Celecoxib may be effective in preventing lung cancer in tobacco smokers. PURPOSE: Phase II trial to study the effectiveness of celecoxib in preventing non-small cell lung cancer in tobacco smokers.
Interventions
- DRUG celecoxib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2001-03 |
| Est. Completion | 2009-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00020878
The ClinicalTrials.gov registry entry for NCT00020878 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which celecoxib is the first listed.
NCT00020878 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00020878 about?
NCT00020878 is a clinical study titled "Celecoxib in Preventing Non-Small Cell Lung Cancer in Tobacco Smokers". RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. Celecoxib may be effective in preventing lung cancer in tobacco smokers. PURPOSE: Phase II trial to study the effectiveness of celecoxib in preventing non-small cell lung cancer in tobacco sm...
What is the current status of trial NCT00020878?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2001-03. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00020878?
The interventions under investigation include: celecoxib (DRUG).
Who is sponsoring clinical trial NCT00020878?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.